We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This research is an output from the Drugs for Neglected Diseases (DNDi) initiative
Employment Tribunal decision.
Examines the treatment of multi-drug resistant-TB patients within and outside the National Tuberculosis Control Program
To evaluate patient characteristics resuming ART after treatment interruption and reason for interrupting ART
Veterinary products seized during an FDA (US Food and Drug Administration) Operation.
Measures time between onset of tuberculosis (TB) symptoms and start of treatment
Drug development involving international partnerships and independent funding mechanisms is a powerful new way to develop drugs for tropical diseases
Chagas disease remains an important public health issue in many Central and South American countries
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).